**Core tip:** This review was designed to provide present evidence of the indication, technique, outcomes, benefits, and risks of colon stenting and emergency surgery in acute malignant colonic obstruction through the analysis of previously published studies with 1A evidence and current guidelines.

INTRODUCTION
============

According to the American Cancer Society\[[@B1]\] and Colorectal Cancer Statistics 2017\[[@B2]\], colorectal cancer (CRC) is one of the most common malignancies in the United States and the second leading cause of cancer death in the world in 2018. Acute abdomen obstructive (AAO) due to CRC occurs in 8%-29% of patients and is a gastrointestinal (GI) emergency requiring urgent decompression considering the risk of necrosis and perforation as a result of massive distension of the loop. Bacterial translocation and imbalance of intracorporal electrolytes also contribute to the high mortality rate\[[@B3]-[@B5]\].

In the 1990s, self-expanding metal stents (SEMS) appeared, which were a watershed in the treatment of patients in GI surgical emergencies\[[@B6]-[@B9]\]. The initial studies had encouraging results since the use of the stent could remove the patient from a surgical emergency, improve their performance status, reducing not only morbidity but mortality and preventing a colostomy giving them a better quality of life (QOL)\[[@B10]-[@B13]\]. Palliative patients were major beneficiaries of this development since they often can not tolerate more invasive surgical procedures, and up to 94% of emergency surgeries can be avoided with this strategy\[[@B14]\].

For patients presenting with acute left-sided colonic obstruction secondary to an operable malignancy, SEMS placement allows colonic decompression, preoperative bowel preparation, and preoperative colonoscopy to assess for synchronous cancers. Patients may then undergo a one-stage surgical procedure, possibly laparoscopically, with a primary anastomosis\[[@B6],[@B15]\].

In the past, emergency surgery (ES) has been the primary treatment for AAO, although morbidity and surgical mortality rates are higher in these settings than in elective procedures\[[@B16]\]. ES in this setting is associated with a morbidity rate of 32%-64%\[[@B17]\] and mortality rate of 15%-34%.

There are currently 13 randomized controlled trials (RCTs)\[[@B18]-[@B30]\] and 20 meta-analyses\[[@B7],[@B14],[@B15],[@B30]-[@B47]\] reporting results of colonic SEMS as a bridge to surgery. There are also 4 RCTs\[[@B12],[@B48]-[@B50]\] and 4 meta-analyses\[[@B42],[@B51]-[@B53]\] evaluating SEMS for palliative indications. Nevertheless, there are still doubts about the management of AAO by CRC.

This review was designed to provide present evidence for the indications, techniques, outcomes, benefits and risks of these treatments in the management of acute malignant colonic obstruction (MCO) through the analysis of previously published studies and current guidelines.

SEARCH METHODS
==============

Study selection
---------------

A systematic search was performed, with no restriction regarding the idiom or the year of publication, since the inception of database till October 01, 2018 using PubMed, MEDLINE, Web of Science, EMBASE, and Cochran Central Register of Controlled Trials databases. Both MeSH and non-MeSH terms were included in the search.

Eligibility criteria
--------------------

All studies comparing colonic stent *vs* surgery for acute malignant large bowel obstruction were included. Relevant studies about colonoscopy, acute obstructive abdomen due to neoplasia were also included.

Exclusion criteria
------------------

Studies were excluded from this review according to the following criteria: use of the stent for benign treatment, stents placed by an interventional radiologist; unclear or missing data for the outcomes variables.

Assessment of study quality
---------------------------

Randomized trials (Evidence 1A) were prioritized as well as previous reviews on the topic.

INITIAL CONSIDERATIONS
======================

Bowel obstruction is deﬁned as the absence of gas or bowel movements for ≥ 24 h, and it is associated with abdominal pain, abdominal bloating or distension and the visualization of dilated colon on an abdominal imaging\[[@B16],[@B54]\].

Computed tomography (CT) is recommended when MCO is suspected and\[[@B55]\] can confirm obstruction and clarify the level of the stricture, as well as identify the etiology of obstruction\[[@B41],[@B56]\] .

STENTS INDICATIONS
==================

Indications
-----------

Currently, indications for stent placement in patients with MCO are: Stent as a "bridge to surgery" to avoid ES\[[@B57]\]; Palliative CRC patients\[[@B58]\]; Extra colonic tumors causing acute abdominal obstruction (*e.g*., advanced gastric cancer, ovarian cancer)\[[@B59]-[@B61]\].

Contraindications
-----------------

Signs of systemic toxicity or septic shock as these are signs of colonic ischemia or perforation\[[@B62]\]. Intra-abdominal abscess. Excessively dilated cecum (\> 9 cm) as endoscopic insufflation may precipitate colonic perforation. Distal rectal lesions that would require the stent to cross the dentate line as this can induce severe pain, tenesmus, and rectal bleeding\[[@B34],[@B63]\]. Persistent coagulopathy (relative)\[[@B64]\].

Extrinsic obstruction
---------------------

Rarely, extrinsic lesions can compress the colon causing MCO. The most frequent causes of extrinsic obstruction are primary pelvic malignancies (ovarian, uterine, and bladder cancer), advanced gastric cancer or metastatic lesions to the pelvis\[[@B65]\]. Extrinsic obstruction occurs more frequently in the left colon, especially in the distal region, and in these cases endoscopic tissue biopsy is not technically possible and the exact etiology and extent of obstruction is often not clear\[[@B60],[@B61]\].

Patients with extrinsic colonic obsltruction, in the vast majority of cases, have advanced disease with reduced life expectancy and no potential curative surgical ressection. .Nevertheless, the technical and clinical success of stenting in these cases, is less effective then when apllyied to primary colorrectal tumors, and there no ideal option\[[@B59],[@B65]\].

STENT and chemotherapy
----------------------

Whether it is in palliative patients or in those who will use the stent as a bridge for elective surgery, there is a high chance of colonic perforation if chemotherapy is associated, especially with angiogenesis inhibitors such as bevacizumab\[[@B66],[@B67]\]. The European Society of Gastrointestinal Endoscopy does not recommend the combination therapy of stent with antiangiogenic drugs\[[@B62]\].

Chemotherapy for metastatic CRC (CRCM) has evolved in the last decade from cytotoxic agents to molecular targeting agents\[[@B68]\]. Currently, four cytotoxic agents \[5-fluorouracil (5-FU), capecitabine, irinotecan, oxaliplatin\]\[[@B69],[@B70]\] and five molecular targeting agents \[bevacizumab (BV), cetuximab, panitumumab, aflibercept, and regorafenib\] are used as chemotherapeutics for CRCM, given in combination or alone\[[@B71]-[@B74]\].

New chemotherapy schedules can take approximately 24 mo\[[@B75]-[@B77]\], twelve months longer than that used in the classic 5-FU + leucovorin scheme\[[@B78]\]. Chemotherapy decreases the risk of tumor ingrowth compared to the use of SEMS alone; however, chemotherapy is considered a significant risk factor for long-term complications, including perforation and stent migration\[[@B79]\]. Regarding the use of bevacizumab, studies have reported that it is an independent risk factor for late complications and even without a stent increased the risk of perforation by 19.6 times\[[@B80],[@B81]\].

Considering the benefits of increased survival and QOL achieved by new chemotherapies, there still is a role for stents in palliation, however, with parsimony\[[@B66],[@B82]\].

TYPES OF COLONIC STENTS
=======================

SEMS may be either covered or uncovered; however only uncovered are available in the United States. All colorectal stents work very similarly\[[@B83]\].

The available stents are mostly made of a nickel-titanium metal alloy (nitinol) (Figure [1](#F1){ref-type="fig"}). An important characteristic of this material is that it is malleable at low temperatures and has strong radial force at body temperature without losing flexibility\[[@B84]\].

![Stent models, left to right: Colonic Z (Cook), Evolution colonic (Cook), Wallflex (Boston), D-type colonic not covered (Taewoog), type colonic covered (Taewoong). All FDA approved stents.](WJGE-11-193-g001){#F1}

Delivery systems can be introduced into the colon parallel to the endoscope, over the wire (OTW) or through the scope (TTS). TTS is typically preferred and facilitates the treatment of right colon lesions\[[@B3],[@B85]\]. Commercially available stents are reported in Table [1](#T1){ref-type="table"}.

###### 

Commercially available colorectal stents

  **Manufacturer and model**                                      **Material**      **Delivery system**   **Diameter (mm)**        **Flare**   **Flare diameter (mm)**   **Length (mm)**              **Covered/uncovered**
  --------------------------------------------------------------- ----------------- --------------------- ------------------------ ----------- ------------------------- ---------------------------- -----------------------------
  Boston Scientific                                                                                                                                                                                   
  Wallstent Colonic[1](#T1FN1){ref-type="table-fn"}               Nitinol           TTS                   22, 25                   1           27, 30                    60, 90, 120                  Uncovered
  Wallstent Endoprothesis[1](#T1FN1){ref-type="table-fn"}         Stainless steel   TTS                   20, 22                   0           --                        60, 90, 120                  Uncovered
  Ultraflex Precision Colonic[1](#T1FN1){ref-type="table-fn"}     Nitinol           OTW                   25                       1           30                        57, 87, 117                  Uncovered
  Micro-Tech Europe                                                                 OTW                   30                       0           --                        75, 88, 112, 123, 136        Uncovered/fully covered
  Micro-Tech Europe Colon and Rectum stent                        Nitinol           OTW                   20, 30                   2           26, 36                    60, 80, 100                  Uncovered/partially covered
  Leufen Medical GmbH                                                               TTS                   25                       2           30                        80, 100, 120                 Uncovered
  Colon Rectum Stent                                              Nitinol           OTW                   25, 30                   2           30, 36                    80, 100                      Uncovered/partially covered
                                                                                    TTS                   25                       2           30                        80, 100                      Uncovered
  Cook                                                                                                                                                                                                
  Evolution Colonic[1](#T1FN1){ref-type="table-fn"}               Nitinol           TTS                   25                       2           30                        60, 80,100                   Uncovered
  MI Tech                                                                                                                                                                                             
  Hanarostent Colon/Rectum[1](#T1FN1){ref-type="table-fn"}        Nitinol           TTS                   22, 24                   2           26, 28                    80, 110, 140, 170            Uncovered
                                                                                    TTS/OTW               20, 24                   2           26, 32                    60, 90, 100, 120, 130, 160   Fully covered
                                                                                    OTW                   24                       2           32                        50,80,110,150                Fully Covered
  Choostent Colon/Rectum                                          Nitinol           OTW                   22,24                    2           30, 32                    100, 180                     Fully covered
  EndoChoice                                                                        OTW                   22,24                    2           30, 32                    80, 120                      Fully covered
  Bonastent                                                       Nitinol           TTS                   22, 24, 26               0           --                        60, 80, 100                  Uncovered/partially covered
  Taewoong Medical                                                                                                                                                                                    
  Niti-S Enteral Colonic D-type[1](#T1FN1){ref-type="table-fn"}   Nitinol           TTS                   18, 20, 22, 24, 26, 28   0           --                        60, 80, 100, 120             Uncovered
  Niti-S Enteral Colonic S-type[1](#T1FN1){ref-type="table-fn"}   Nitinol           TTS                   20, 22                   2           28, 30                    60, 80, 100, 120             Fully/partially covered
                                                                                    OTW                   22, 24, 26, 28           2           30, 32, 34                60, 80, 100, 120             Fully/partially covered
  Self expandable Stent                                                                                                                                                                               
  Braile Endomédica                                               Nitinol           TTS                   26                       0           \-                        70, 100, 130                 Partially covered

FDA approved. TTS: Through the scope; OTW: Over the wire.

Covered vs uncovered stents
---------------------------

Covered stents are mainly used in the establishment of colonvesical fistulas, coloenteric and cervicovaginal malignancies\[[@B86]\]. Although the theoretical advantage of covered stents is that they have a lower risk of tumor ingrowth, they are also more likely to migrate compared to uncovered stents.

In a randomized trial\[[@B84]\] including 151 patients with AAO by CRC, there was no difference in the clinical success rate for the placement of covered stents compared with uncovered stents (96% *vs* 92%). There was a higher rate of migration (21% *vs* 2%) and a trend towards less tumor ingrowth in covered stents (4% *vs* 15%). There were no differences in relation to adverse events or obstruction by debris.

ADDITIONAL DIAGNOSTICS AND EXAMS
================================

The diagnosis of colonic obstruction is made through symptoms and complemented by imaging tests (for example, simple radiography and/or CT (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). Additional exams such as colonoscopy may be performed prior to stent placement procedure. Pre-procedure colonoscopy may provide direct endoscopic visualization of the site of obstruction, and tissue biopsies can be performed for histological diagnosis if needed. Important tumors characteristics can also be ascertained , such as precise location, length of stenosis, topography (extrinsic or intrinsic), and adjacent anatomic considerations (angulation, mucosa inflammation, ischemia or diverticulae)\[[@B87],[@B88]\].

![Virtual Colonoscopy showing a malignant stricture in the distal left colon.](WJGE-11-193-g002){#F2}

![Radiography images. A: Radiography showing signs of a distal obstruction; B: Radiography of the same patient showing improvement after stenting and decompression. Figure [4](#F4){ref-type="fig"} Stents procedure. A: Guide-wire placement through the stricture after contrast study; B: Stent deploying through the scope; C: Stent placement showing the stricture in the middle of the stent; D: Final stent position.](WJGE-11-193-g003){#F3}

![Stents procedure. A: Guide-wire placement through the stricture after contrast study; B: Stent deploying through the scope; C: Stent placement showing the stricture in the middle of the stent; D: Final stent position.](WJGE-11-193-g004){#F4}

The degree of obstruction should be assessed by attempting to navigate the stenosis with the endoscope; however, it is not necessary to advance the endoscope through the tumor to perform stent placement. Examination with a water-soluble enema or rectal CT may be useful, but not absolutely necessary, to obtain a map of the colonic anatomy, length of stenosis, and degree of obstruction. This radiographic evaluation may also identify additional sites of obstruction that may prevent successful stent placement\[[@B33],[@B56]\].

PROCEDURE
=========

Preparation of colon
--------------------

Although patients may have AAO, bowel preparation should be attempted and preparation depends on location and degree of obstruction: For partial obstruction in the distal colon, two water-soluble enemas (250-500 mL) are sufficient; For partial obstruction of a proximal lesion, oral colon preparation may be attempted and discontinued if symptoms such as abdominal pain or emesis occur\[[@B89]\]; For complete colonic obstruction, oral preparations are contraindicated due to high risk of perforation. Rectal water-soluble enemas should be considered\[[@B90]\].

Use of pre-procedure antibiotics
--------------------------------

Prophylaxis is not mandatory for patients undergoing stenting. However, in patients with complete obstruction, we suggest prophylaxis considering the risk of micro perforation and bacteremia during insufflation\[[@B62],[@B91]\].

Sedation
--------

Lower endoscopic procedures can typically be performed anywhere on the sedation spectrum, from sedation to general anesthesia. However, this is not applied to patients who need to use a stent because they are in an obstructive emergency. General anesthesia with active airway management should be mainly performed to prevent bronchoaspiration with feculent emesis for example and also does not move at the time of the procedure increasing the chance of perforation\[[@B92],[@B93]\].

Procedure
---------

Stents are always placed under endoscopic guidance with the aid of fluoroscopy\[[@B62],[@B94]\] (Figure [4](#F4){ref-type="fig"}). During colonoscopy, limited insufflation should be used to minimize the risk of perforation due to the risk of a closed loop between the obstructive lesion and the ileocecal valve. The use of carbon dioxide has largely supplanted air for this procedure, and most complex therapeutic cases\[[@B95]\]. A water-immersed colonoscopy is another technique that can be used to minimize bowel distention\[[@B96]\].

Upon reaching the lesion, an attempt can be made to cross the stenosis with the endoscope. However, if the endoscope does not traverse through the obstruction easily, a 0.035-inch guidewire may be passed through stenosis under fluoroscopic guidance.

The first RCT\[[@B48]\] comparing stenting versus ES in palliative patients included balloon dilation of the stenosis prior to stent placement, which is no longer considered and acceptable practice. If endoscope passage through the stenosis is not possible, fluoroscopic guidance is preferred to balloon dilation as the latter is associated with increased risk of perforation\[[@B84]\].

After confirming the length of stenosis, either through the passage of the endoscope or with contrast injection under fluoroscopic guidance, technique of stent placement depends on the type of stent being used.

STENT PLACEMENT
===============

TTS
---

For this method, a therapeutic endoscope is needed to introduce the stent through the working channel (Figure [5](#F5){ref-type="fig"}). If the stenosis cannot be traversed, contrast injection helps to delineate the stenosis and to confirm guidewire placement trough the stenosis under fluoroscopy.

![Stent placement by Through the scope technique.](WJGE-11-193-g005){#F5}

The stent is then passed over the guidewire to the proximal margin of the tumor and then implanted under fluoroscopic guidance and endoscopic visualization of the distal portion of the stent. Each end of the stent must be at least 2 cm longer than the stenosis (4 cm of safety margin), as these stents typically shorten after deployment and expansion\[[@B62],[@B85],[@B97]\] (Figure [6](#F6){ref-type="fig"}).

![The stent is passed over the guidewire to the proximal margin of the tumor and then implanted under fluoroscopic guidance and endoscopic visualization of the distal portion of the stent. A: Malignant lesion causing colonic stenosis; B: Stent deployment; C: Stent immediately after deployment; D: Fecal contents coming through the stent after decompression.](WJGE-11-193-g006){#F6}

To prevent migration, it is not recommended that the endoscope be passed through the stent once the stent is placed, although endoscopic/fluoroscopic visualization should be used to rule out early complications.

OTW
---

After the guidewire placement, endoscopic visualization is still preferred, however, not absolutely essential\[[@B64]\]. This technique may be helpful when there is an acute angulation or others factors limiting endoscopic visualization. The stent is inserted over the guidewire and implanted under fluoroscopic guidance (Figure [7](#F7){ref-type="fig"}).

![Stent placement by Over-the-wire technique.](WJGE-11-193-g007){#F7}

The correct position of the stent reveals a waist in the center of the stent that crosses the tumor with a widening of the proximal and distal ends. If either end of the stent is not adequately expanded to produce a waist, it may be too short to cross the stenosis. In such cases, a second or third overlapping stent can be used without removing the first to completely cross the stenosis\[[@B98]\].

POST-PROCEDURE CARE
===================

After stent placement in the left colon, stool softeners should be used to prevent fecal impaction within the stent\[[@B62]\]. Low-residue diets added to the use of polyethylene glycol should be followed. Laxative dose titration may be required. Patients should be instructed to avoid high-fiber foods, such as many fruits, vegetables, and whole grains\[[@B98]\]. Patients with stents in the transverse or right colon may resume normal diets, as the feces in these locations is typically liquid\[[@B98]\].

ADVERSE EVENTS
==============

Colonic SEMS placement seems to be relatively safe and effective and has some advantages over surgery, but is associated with an overall complication rate of up to 25%\[[@B99]-[@B101]\]. Clinical and technical failures are greater in strictures longer than 4 cm and more adverse events, especially perforation, are reported in complete obstruction\[[@B80]\].

Adverse events may be categorized into minor and major or early (≤ 30 d) and late (\> 30 d). Example of major adverse events includes intestinal perforation, obstruction requiring new procedures, bleeding, migration, aspiration during sedation, and death. Typical minor adverse events includes abdominal pain, colic and tenesmus\[[@B3]\].

Perforation
-----------

This may occur late or immediately after the procedure and is associated with poor outcomes\[[@B9]\]. Several factors can increase the risk of perforation including radiotherapy and chemotherapy as well as colonic anatomy\[[@B3],[@B66],[@B67]\]. A meta-analysis in 2018, including palliative patients revealed a perforation rate of 9.5%\[[@B53]\].

Stent migration
---------------

Occurs in approximately 10% when used as a bridge to surgery and in 1% of palliative patients, usually one week after insertion. The main causes of migration include incorrect stent selection, stent dimensions being too narrow, small, or short, mild stenosis that is not obstructive, and improvement of stenosis due to radiotherapy or chemotherapy\[[@B7],[@B32],[@B53]\]. Other less common factors that may precipitate stent migration include extrinsic lesion, dilation of stenosis, or use of covered stents.

Stent obstruction
-----------------

Occurs in approximately 11.1% of palliative patients. This occurs due to tumor overgrowth at the proximal or distal margins of the stent or through tumor in growth through the cells of the stent\[[@B53]\]. Possible endoscopic treatments for stent obstruction include laser ablation of the tumor, argon plasma coagulation or placement of new stent\[[@B48],[@B102]\].

Hemorrhages
-----------

Immediate post-procedure bleeding may occur due to irritation of the colon mucosa by stent flanges, tumor friability, trauma due to either stent passage or guidewire placement, or endoscope trauma. Late bleeding may be due to stent related ulcerations or erosions in the colonic mucosa\[[@B64]\].

Pain
----

Mild abdominal pain is common and may be prolonged up to five days after stenting. For this, the use of simple analgesics can be helpful. Opioid analgesics may be required within 48 to 72 h of stenting due to expansion of the stent with consequent worsening of pain\[[@B34],[@B85]\]. For low rectal lesions, stent-induced irritation of the nerve endings near the squamous-columnar junction should be avoided.

Colonic decompression failure
-----------------------------

Despite the high technical success of stent implantation, failure of colonic decompression can occur. This often results in urgent surgery and is considered a serious adverse event\[[@B9],[@B103]\]. The most common reasons are described below\[[@B91]\]: Other additional sites of intestinal obstruction; Stent shorter than stenosis length; Incomplete stent expansion; Stent migration; Underlying motility disorder; Fecal impaction.

EVIDENCE 1A IN LITERATURE
=========================

Stent as bridge for surgery (Figure [8](#F8){ref-type="fig"})
-------------------------------------------------------------

![Specimen and stent. A: Specimen after surgery showing the stent crossing the lesion; B: Image of the stent and the malignant lesion after resection.](WJGE-11-193-g008){#F8}

In a recent systematic review and meta-analysis performed by Arezzo et al\[[@B15]\], used only RCTs with a total of eight articles: Mortality rate of 9.9% in ES group and 9,6% was demonstrated in the SEMS group; Adverse events rate of 51.2% was demonstrated in the ES group versus 33.9% in the patients with stent; Temporary colostomy rate of 33.9% was demonstrated in the stent group *vs* 51.4% of patients undergoing ES; The definitive colostomy rate of 22.2% was demonstrated in the stent group versus 35.2% demonstrated in patients of ES group; Regarding the success of the primary anastomosis, there was a 70% rate for the stent group versus 54.1% for the ES group; The need for surgical intervention due to adverse events was 10.9% in the patient with SEMS versus 8.7% in the ES group; The operating time: 172 min in patients submitted ES and 146 minutes in the SEMS group; The hospitalization time was, on average, 14.5 d for patients submitted to ES and 15.5 d for those submitted to STENT; Tumor recurrence was 40.5% in patients in the stent group and 26.6% in the ES group (Table [2](#T2){ref-type="table"}).

###### 

Outcomes in studies with evidence 1A (Metanalyses of randomized studies)

  **Outcome**            **Stent as bridge to surgery;** **Arezzo et al**\[[@B13]\]**, 2017**   **Stent as bridge to surgery;** **Arezzo et al**\[[@B13]\]**, 2017**   **Palliative patients;** **Ribeiro *et a*l**\[[@B51]\]**, 2018**   **Palliative patients;** **Ribeiro et al**\[[@B51]\]**, 2018**
  ---------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------ ----------------------------------------------------------------
  No. of patients        251                                                                    246                                                                    63                                                                 62
  Mortality              9.6%                                                                   9.9%                                                                   6.3%                                                               6.4%
  Adverse events         33.9%                                                                  51.2%                                                                  36.5%                                                              24.1%
  Survival               NA                                                                     NA                                                                     279 d                                                              244 d
  Clinical success       NA                                                                     NA                                                                     84%                                                                96%
  Technical success      NA                                                                     NA                                                                     84%                                                                96%
  Temporary colostomy    33.9%                                                                  51.4%                                                                  NA                                                                 NA
  Definitive colostomy   22.2%                                                                  35.2%                                                                  14.3%                                                              86.1%
  Primary anastomosis    70%                                                                    54.1%                                                                  NA                                                                 NA
  Hospital stay          15.5 d                                                                 14.5 d                                                                 17.5 d                                                             35.5 d
  ICU hospitalization    NA                                                                     NA                                                                     0                                                                  1 d

NA: Not available; ICU: Intensive care unit.

Stent in palliative patients
----------------------------

A recent systematic review and meta-analysis performed by Ribeiro et al\[[@B53]\] in 2018, compared the use of stents to surgical intervention, only in palliative patients, as a definitive treatment. Only RCTs were included, with a total of four articles including 125 patients: 30-d mortality rate of 6.4% in patients submitted ES *vs* 6.3% in the stent group; Analyzed survival was 244 d in the ES group and 279 d in the SEMS group; Clinical success was 84% in the SEMS group and 96% in the ES group; 30-d adverse event rates were 36.5% in the stent group and 24% in the ES group; Technical success was favorable to the surgery group (84% for stent group and 97% for ES group); Rate of permanent colostomy was higher in the surgery group (86.1% versus 14.3%); Length of intensive care stay was not statistically significant between groups; The mean time of hospitalization was 35.5 d for patients undergoing ES and 17.5 for the stent group; Perforation was the most common complication found in the stent group, representing 42.8% of total adverse events, with six of sixty-three patients (9.5%) having perforation, one (1.5%) migration and seven (11.1%) obstruction.

CONCLUSION
==========

Studies comparing emergent surgery to the use of stents as a bridge to surgery demonstrate a lower rate of a temporary and permanent stoma and a lower short-term morbidity, in a patient undergoing stent placement. This may also positively influence patient's QOL, however, questions remain regarding longer-term durability. Until more long-term oncological studies are available, stenting cannot be established as the gold standard of treatment. Regarding the use of stents in acute abdominal obstruction in palliative patients, mean survival, early complications, ICU length of stay, and mortality are similar to surgery. Surgery was associated with greater clinical success, while stents demonstrated shorter hospital stay and fewer definitive stomas. Therefore, stenting may be an alternative for patients with incurable obstructive tumors in acute abdomen, with the advantage of early hospital discharge and the potential for improved QOL with avoidance of a permanent stoma.
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